Back to Explorer

Using the Inactive Ingredient Database Guidance for Industry

DraftCenter for Drug Evaluation and Research07/11/2019

Description

This guidance describes the Food and Drug Administration’s (FDA’s) Inactive Ingredient Database (IID) and provides recommendations for how to use the IID in the development of drug products. The guidance also describes how the IID can be used in evaluating excipient safety, which can affect application filing and scientific review. In addition, this guidance discusses how the IID is structured; the data regarding excipients in the IID; and how nomenclature, maximum potency levels, and units of measure are presented in the IID. Lastly, the guidance is intended to give IID users a clearer understanding of the database’s benefits and limitations.

Scope & Applicability

Product Classes

1
Combination Product

Products combining drug, device, or biological constituents; Generally recommended for Enhanced Documentation; Requires 14971-based framework incorporating ICH Q9; A drug-device combination where the device constituent part detects ingestion.

Stakeholders

2
sponsor

responsible for justifying omission of studies

applicant

entity submitting marketing applications

Regulatory Context

Attributes

4
Maximum Potency

highest level of an excipient in an FDA-approved product; IID currently provides only the maximum potency per dosage unit

Maximum Daily Exposure

limit for excipients like antioxidants or pH modifiers

Maximum Daily Intake

solid oral drug product with a maximum daily intake of 2.5 grams

Total Daily Exposure

assessment of appropriateness of excipients based on total daily exposure

Related CFR Sections (2)

See Also (8)

Using the Inactive Ingredient Database Guidance for Industry | Guideline Explorer | BioRegHub